BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 20177404)

  • 1. Mismatch repair deficient colorectal cancer in the era of personalized treatment.
    Hewish M; Lord CJ; Martin SA; Cunningham D; Ashworth A
    Nat Rev Clin Oncol; 2010 Apr; 7(4):197-208. PubMed ID: 20177404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
    Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L
    Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
    Stadler ZK
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):29-41. PubMed ID: 25475571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.
    Leicher LW; Lammertink MHA; Offerman SR; Morreau H; de Jong MM; de Groot JWB; van Westreenen HL; Vasen HFA; de Vos Tot Nederveen Cappel WH
    Scand J Gastroenterol; 2018 May; 53(5):632-636. PubMed ID: 29161904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas.
    Maletzki C; Stier S; Gruenert U; Gock M; Ostwald C; Prall F; Linnebacher M
    PLoS One; 2012; 7(12):e52485. PubMed ID: 23300683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
    Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
    Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.
    Zaanan A; Meunier K; Sangar F; Fléjou JF; Praz F
    Cell Oncol (Dordr); 2011 Jun; 34(3):155-76. PubMed ID: 21484480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
    Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
    Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
    Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
    Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].
    Cohen R; Cervera P; Svrcek M; Dumont C; Garcia ML; Chibaudel B; de Gramont A; Pocard M; Duval A; Fléjou JF; André T
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S72-81. PubMed ID: 26118880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
    Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
    Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
    Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
    PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of MMR-deficient colorectal cancer.
    Devaud N; Gallinger S
    Fam Cancer; 2013 Jun; 12(2):301-6. PubMed ID: 23539382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biology in clinical cancer research: the example of digestive cancers].
    Lièvre A; Laurent-Puig P
    Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
    Tejpar S; Saridaki Z; Delorenzi M; Bosman F; Roth AD
    J Natl Cancer Inst; 2011 Jun; 103(11):841-4. PubMed ID: 21597023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.